Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Studies reveal benefits of catheter ablation system for atrial fibrillation

Ablation Frontiers : 25 June, 2008  (Company News)
Ablation Frontiers has announced that two studies reporting positive findings about its novel atrial fibrillation catheter ablation system have been presented at the Cardiostim World Congress, a premier meeting for physicians that treat cardiac rhythm disorders.
Dr Stefan Weber of the University Clinic at Regensburg, Germany, presented results of a study of 12 patients with paroxysmal atrial fibrillation (PAF). Using the company's PVAC (Pulmonary Vein Ablation Catheter) and GENius RF generator, Dr Weber reported success in isolating 98 percent of pulmonary veins with a remarkably short average ablation time of 84 +/- 9 minutes. The total time of radiofrequency (RF) energy needed to successfully isolate the pulmonary veins was 22.4 +/- 2.9 minutes.

'We found that mapping and ablation of the pulmonary veins using a single catheter, without 3D navigation or robotic steering, could be performed safely and effectively with short procedure times,' stated Dr Weber. 'Thus, this system may be of high interest for all centers who would like to increase throughput for AF ablation.'

The second study, led by Dr Christoph Scharf and presented by Dr Lam Dang of Klinik Im Park Hospital in Zurich, Switzerland, utilised the same novel Catheter ablation technology in a total of 45 patients with long standing persistent AF. The study utilised two additional catheters from Ablation Frontiers, MASC (Multi-Array Septal Catheter) and MAAC (Multi-Array Ablation Catheter) designed to find and ablate specific ablation targets called CFAEs (Complex Fractionated Atrial Electrograms). Six month follow up data was presented for 37 patients, with 78 percent free of AF after an average procedure time of 162 +/- 36 minutes. Dr Scharf noted the particularly low re-do procedure rate of 13.5 percent and the absence of left atrial flutters after the procedure.

'These early results are very promising and procedure times have been significantly reduced,' stated Dr Scharf. 'Using unipolar:bipolar RF energy for the ablation is safer and more effective in our experience. This is an important aspect to this system, as tipped-catheters and conventional higher power RF generators have been associated with significant complications.'

The company's innovative multi-electrode mapping and ablation catheters are used in conjunction with its duty-cycled radiofrequency (RF) generator. Each catheter's adaptable shape facilitates access to and good tissue contact with the left atrial regions that require ablation to terminate atrial fibrillation. The temperature controlled, power limited energy source was specifically designed to reduce the risk of complications seen with conventional higher-energy power sources.

'While isolation of the pulmonary veins can be effective in treating paroxysmal AF, long-standing persistent AF requires that other areas of the left atrium be specifically targeted. Conventional ablation technology offers only one therapeutic option for both disease states, which has produced moderate success, relatively high rates of complications, and long procedure times. Ablation Frontiers' family of catheters delivers innovative solutions for treating both paroxysmal and long standing persistent AF patients,' stated Keegan Harper, chief executive officer of Ablation Frontiers. 'We are very gratified to see our products working in both AF patient populations with high success rates, very low complication rates, and considerably shortened procedure times.'

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo